Bone Care International Announces Patent Issuance

Bone Care International Announces Patent Issuance
Patent for Stabilized Hydroxyvitamin D2 Products Covers Hectorol(R)
(doxercalciferol) 


MIDDLETON, Wis., June 7  /PRNewswire-FirstCall/ -- Bone Care International,
Inc. (NASDAQ:BCII) announced today that the U.S. Patent and Trademark Office
has issued to it U.S. Patent Number 6,903,083 entitled "Stabilized
hydroxyvitamin D."  The patent claims a stabilized 1alpha-hydroxyvitamin D2 and
pharmaceutical products or compositions that include such an active component. 
The stabilized hydroxyvitamin D2 products covered under this patent are
characterized by a purity profile defined by levels of impurities and residual
solvents.  Hectorol(R), Bone Care's novel vitamin D hormone therapy that treats
secondary hyperparathyroidism in patients with moderate to severe chronic
kidney disease and end-stage renal disease, is covered by this new composition
of matter patent that will expire in 2021.

Mr. Paul Berns, President and Chief Executive Officer, Bone Care International
stated, "This new patent on stabilized hydroxyvitamin D2 products expands the
Hectorol(R)-related patent portfolio and extends the protected time horizon."

Bone Care International (http://www.bonecare.com/) is a specialty
pharmaceutical company engaged in the discovery, development and
commercialization of innovative therapeutic products to treat the unmet medical
needs of patients with debilitating conditions and life-threatening diseases. 
Our current commercial and therapeutic focus is in nephrology, utilizing
Hectorol(R), a novel vitamin D hormone therapy, to treat secondary
hyperparathyroidism in patients with moderate to severe chronic kidney disease
and end-stage renal disease.  In addition to chronic kidney disease, the
Company is developing vitamin D hormone therapies to treat hyperproliferative
disorders such as cancer and psoriasis.

  Contact
   Bone Care International, Inc.
   Brian J. Hayden
   Chief Financial officer
   608-662-7800



This press release contains forward-looking statements. Statements relating to
future sales, costs of sales, other expenses, profitability, financial
resources, or products and production schedules, or statements that predict or
indicate future events and trends and which do not relate solely to historical
matters identify forward-looking statements. Forward-looking statements are
made pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are
based on management's beliefs as well as assumptions made by and information
currently available to management. Accordingly, the Company's actual results
may differ materially from those expressed or implied in such forward-looking
statements due to known and unknown risks and uncertainties that exist in the
Company's operations and business environment, including, among other factors,
the ability of the Company and each of its suppliers of doxercalciferol,
Hectorol(R) Injection and Hectorol(R) Capsules to meet the Company's
anticipated production schedules, technical risks associated with the
development of new products, regulatory policies in the United States and other
countries, risks associated with our ability to avoid or minimize delays in/or
interruption of the manufacture and supply of our products, including the
approvals of regulatory authorities in connection therewith, reimbursement
policies of public and private health care payors, introduction and acceptance
of new drug therapies, competition from existing products and from new products
or technologies, the failure by the Company to produce anticipated cost savings
or improve productivity, the timing and magnitude of capital expenditures and
acquisitions, currency exchange risks, economic and market conditions in the
United States, Europe and the rest of the world, and other risks associated
with the Company's operations. The Company disclaims any obligation to update
any such factors or to publicly announce any revisions to any of the
forward-looking statements contained herein to reflect future events or
developments. 

DATASOURCE: Bone Care International, Inc.



CONTACT:  Brian J. Hayden, Chief Financial officer of Bone Care

International, Inc., 608-662-7800 



Web site:  http://www.bonecare.com/ 

Copyright